Author: Tardieu Michele Slaoui Faouzi Josefonvicz Jacqueline Courty Jose Gamby Chantal Barritault Denis
Publisher: Taylor & Francis Ltd
ISSN: 1568-5624
Source: Journal of Biomaterials Science, Polymer Edition, Vol.1, Iss.1, 1989-01, pp. : 63-70
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
—Heparin has been shown to interact with acidic fibroblast growth factor (aFGF) and to potentiate the biological activity of aFGF on fibroblastic cells. Water-soluble dextran substituted with methyl carboxylic benzylamine and sulfonate groups has been shown to mimic the effect of heparin in its anticoagulant and anticomplement activity. We have studied the effect of a dextran derivative named E (DDE), which had an anticoagulant activity equivalent to 0.5 IU heparin/mg, on the mitogenic activity of aFGF on Chinese hamster fibroblasts (CCL39). DDE interacts with aFGF in a comparable manner to heparin. We have shown that 20μg of heparin or 400μg of DDE added to 1 ml of culture medium has no effect on cell proliferation alone but potentiates the mitogenic activity of aFGF ten fold if aFGF is added at doses corresponding to half maximum stimulation (ED50). We have also studied the effect of various concentrations of heparin and DDE on the binding of 125I-aFGF on bovine brain membranes. Interestingly, the binding of 125I-aFGF increased three-fold as the concentration of heparin was increased up to 0.2μg/ml. At 1μg/ml of heparin, the amount of bound 125I-aFGF is comparable to that obtained in the absence of heparin. At higher concentrations, heparin displaces bound 125I-aFGF, and a 50% displacement is seen with 20μg/ml of heparin. In the presence of DDE, no increase in 125I-aFGF binding is seen and a displacement is obtained with increasing doses. A possible explanation of these results may be the existence of specific receptors to heparin on the cellular membrane. These receptors to heparin apparently do not have an affinity for DDE. Our data show that DDE can replace heparin in its interaction with aFGF and that it has the capacity to potentiate the biological activity of these growth factors. Furthermore, our binding studies suggest that this potentiation is not mediated through the cellular receptor of 125Ι-aFGF. The interaction of heparin with aFGF stabilizes and protects aFGF from chemical and proteolytic degradation. DDE may also be a useful aFGF stabilizer with much weaker hemostatic properties than heparin for in vivo application of FGF.
Related content
By Ueno Masaki Uchida Kentaro Saito Wataru Matsushita Osamu Yogoro Mizuki Nishi Nozomu Ogura Takayuki Hattori Shunji Inoue Gen Tanaka Keisuke Takahira Naonobu Takaso Masashi
Biomedical Materials, Vol. 9, Iss. 3, 2014-06 ,pp. :
Regulation of Astrocytic Tenascin by Basic Fibroblast Growth Factor
By Meiners S. Marone M. Rittenhouse J.L. Geller H.M.
Developmental Biology, Vol. 160, Iss. 2, 1993-12 ,pp. :
Fibroblast Growth Factor-23—A Potential Uremic Toxin
By Kuczera Piotr Adamczak Marcin Wiecek Andrzej
Toxins, Vol. 8, Iss. 12, 2016-12 ,pp. :